Brian E. Fink

2.1k total citations
27 papers, 1.7k citations indexed

About

Brian E. Fink is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Brian E. Fink has authored 27 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 14 papers in Oncology and 9 papers in Organic Chemistry. Recurrent topics in Brian E. Fink's work include HER2/EGFR in Cancer Research (9 papers), Chemical Synthesis and Analysis (8 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Brian E. Fink is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Chemical Synthesis and Analysis (8 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Brian E. Fink collaborates with scholars based in United States, Germany and Sweden. Brian E. Fink's co-authors include Dale L. Boger, Michael P. Hedrick, Winston C. Tse, S.R. Brunette, John A. Katzenellenbogen, Ramji R. Rajendran, Jun Sun, Benita S. Katzenellenbogen, Marvin J. Meyers and Shaun R. Stauffer and has published in prestigious journals such as Journal of the American Chemical Society, American Journal of Public Health and Clinical Cancer Research.

In The Last Decade

Brian E. Fink

27 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian E. Fink United States 17 893 687 426 357 109 27 1.7k
Hai‐Bing Zhou China 31 1.1k 1.3× 1.4k 2.0× 352 0.8× 584 1.6× 141 1.3× 128 2.8k
Ross Weatherman United States 16 662 0.7× 338 0.5× 230 0.5× 640 1.8× 40 0.4× 25 1.3k
Amarnath Natarajan United States 28 1.6k 1.8× 748 1.1× 585 1.4× 92 0.3× 75 0.7× 99 2.8k
Ian R. Hardcastle United Kingdom 31 1.8k 2.0× 1.1k 1.6× 993 2.3× 298 0.8× 149 1.4× 81 3.1k
Bing Xiong China 26 1.5k 1.7× 566 0.8× 243 0.6× 77 0.2× 61 0.6× 143 2.3k
Rahul Palchaudhuri United States 17 1.0k 1.2× 615 0.9× 501 1.2× 241 0.7× 109 1.0× 38 1.9k
Joel C. Barrish United States 29 882 1.0× 1.4k 2.0× 301 0.7× 63 0.2× 48 0.4× 104 2.3k
Jonathan C. Morris Australia 28 914 1.0× 860 1.3× 194 0.5× 57 0.2× 89 0.8× 88 2.3k
John S. Tokarski United States 23 776 0.9× 690 1.0× 438 1.0× 63 0.2× 49 0.4× 43 2.0k
Wim F. A. Steelant United States 22 1.1k 1.2× 753 1.1× 344 0.8× 51 0.1× 55 0.5× 35 2.5k

Countries citing papers authored by Brian E. Fink

Since Specialization
Citations

This map shows the geographic impact of Brian E. Fink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian E. Fink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian E. Fink more than expected).

Fields of papers citing papers by Brian E. Fink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian E. Fink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian E. Fink. The network helps show where Brian E. Fink may publish in the future.

Co-authorship network of co-authors of Brian E. Fink

This figure shows the co-authorship network connecting the top 25 collaborators of Brian E. Fink. A scholar is included among the top collaborators of Brian E. Fink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian E. Fink. Brian E. Fink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wong, Tai W., Francis Y. Lee, Stuart L. Emanuel, et al.. (2011). Antitumor and Antiangiogenic Activities of BMS-690514, an Inhibitor of Human EGF and VEGF Receptor Kinase Families. Clinical Cancer Research. 17(12). 4031–4041. 18 indexed citations
2.
Fink, Brian E., Derek Norris, Harold Mastalerz, et al.. (2010). Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 21(2). 781–785. 23 indexed citations
3.
Chakraborty, Joana, et al.. (2008). Retroviral gene insertion in breast milk mediated lymphomagenesis. Virology. 377(1). 100–109. 10 indexed citations
4.
Kim, Soong‐Hoon, John S. Tokarski, Kenneth J. Leavitt, et al.. (2007). Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkA. Bioorganic & Medicinal Chemistry Letters. 18(2). 634–639. 19 indexed citations
5.
Kellar, Kristen A., Matthew V. Lorenzi, Dan You, et al.. (2006). Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics. Molecular Cancer Therapeutics. 5(6). 1571–1576. 5 indexed citations
6.
Fink, Brian E., Ashvinikumar V. Gavai, John S. Tokarski, et al.. (2006). Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorganic & Medicinal Chemistry Letters. 16(6). 1532–1536. 36 indexed citations
7.
Wong, Tai W., Francis Y. Lee, Chiang Yu, et al.. (2006). Preclinical Antitumor Activity of BMS-599626, a pan-HER Kinase Inhibitor That Inhibits HER1/HER2 Homodimer and Heterodimer Signaling. Clinical Cancer Research. 12(20). 6186–6193. 65 indexed citations
8.
Fink, Brian E., et al.. (2006). New Dual Inhibitors of EGFR and HER2 Protein Tyrosine Kinases.. ChemInform. 37(5). 1 indexed citations
9.
10.
Fink, Brian E., Gregory D. Vite, Harold Mastalerz, et al.. (2005). New dual inhibitors of EGFR and HER2 protein tyrosine kinases. Bioorganic & Medicinal Chemistry Letters. 15(21). 4774–4779. 37 indexed citations
11.
Spires, Thomas, Brian E. Fink, Ellen K. Kick, et al.. (2005). Identification of novel functional inhibitors of 17β-hydroxysteroid dehydrogenase type III (17β-HSD3). The Prostate. 65(2). 159–170. 22 indexed citations
12.
Hunt, John T., Toomas Mitt, R. M. Borzilleri, et al.. (2004). Discovery of the Pyrrolo[2,1-f][1,2,4]triazine Nucleus as a New Kinase Inhibitor Template. Journal of Medicinal Chemistry. 47(16). 4054–4059. 78 indexed citations
13.
Boger, Dale L., Brian E. Fink, S.R. Brunette, Winston C. Tse, & Michael P. Hedrick. (2001). A Simple, High-Resolution Method for Establishing DNA Binding Affinity and Sequence Selectivity. Journal of the American Chemical Society. 123(25). 5878–5891. 493 indexed citations
14.
Boger, Dale L., Michael A. Dechantsreiter, Takahiro Ishii, Brian E. Fink, & Michael P. Hedrick. (2000). Assessment of solution-phase positional scanning libraries based on distamycin A for the discovery of new DNA binding agents. Bioorganic & Medicinal Chemistry. 8(8). 2049–2057. 25 indexed citations
15.
Boger, Dale L., Brian E. Fink, & Michael P. Hedrick. (2000). A new class of highly cytotoxic diketopiperazines. Bioorganic & Medicinal Chemistry Letters. 10(10). 1019–1020. 17 indexed citations
16.
17.
Fink, Brian E., et al.. (1999). Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chemistry & Biology. 6(4). 205–219. 195 indexed citations
18.
Sun, Jun, Marvin J. Meyers, Brian E. Fink, et al.. (1999). Novel Ligands that Function as Selective Estrogens or Antiestrogens for Estrogen Receptor-α or Estrogen Receptor-β*. Endocrinology. 140(2). 800–804. 273 indexed citations
19.
Fink, Brian E., Philip R. Kym, & John A. Katzenellenbogen. (1998). Design, Synthesis, and Conformational Analysis of a Proposed Type I β-Turn Mimic. Journal of the American Chemical Society. 120(18). 4334–4344. 88 indexed citations
20.
Myerberg, David Z., et al.. (1995). Reducing postneonatal mortality in West Virginia: a statewide intervention program targeting risk identified at and after birth.. American Journal of Public Health. 85(5). 631–637. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hai‐Bing Zhou Breakdown of academic impact, for papers by Ross Weatherman Breakdown of academic impact, for papers by Amarnath Natarajan Breakdown of academic impact, for papers by Ian R. Hardcastle Breakdown of academic impact, for papers by Bing Xiong Breakdown of academic impact, for papers by Rahul Palchaudhuri Breakdown of academic impact, for papers by Joel C. Barrish Breakdown of academic impact, for papers by Jonathan C. Morris Breakdown of academic impact, for papers by John S. Tokarski Breakdown of academic impact, for papers by Wim F. A. Steelant
Rankless by CCL
2026